The table below shows Bristol-Myers Squibb Company's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$14.16B
$15.19B
$13.86B
$13.07B
$16.21B
$14.05B
Capital expenditure
$1.31B
$1.25B
$1.21B
$1.12B
$973.00M
$753.00M
Investing cash flow
-$4.13B
-$21.35B
-$2.29B
-$1.06B
-$538.00M
-$10.86B
Dividends paid
$5.04B
$4.86B
$4.74B
$4.63B
$4.40B
BMY operating cash flow (10-K history)
Bristol-Myers Squibb Company reported operating cash flow of $14.16B for fiscal year 2025. That is down 6.8% from $15.19B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $3.06B (FY 2016) to $14.16B. Figures come from the company's audited annual reports as filed with the SEC.
